Slow-flow phenomenon after drug-coated balloon angioplasty for lower-extremity arteries is associated with lack of prescribing of calcium channel blockers

Arita, Yoh; Fukui, Tomoki; Ogasawara, Nobuyuki

doi:10.1016/j.ihj.2023.01.005

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Omega-hexatoxin-Hv1a can be used as an alternative to chemical calcium channel blockers to prevent IRI. When used in clinical practice, the toxin can be considered as a new class of drugs that enables cells and tissues to adapt to a rapidly changing metabolism during reperfusion, for example, in balloon angioplasty [ 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

Protective Effect of Peptide Calcium Channel Blocker Omega-Hexatoxin-Hv1a on Epithelial Cell during Ischemia–Reperfusion Injury

Iurova,

Rastorgueva,

Beloborodov

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Ischemia–reperfusion injury (IRI) is a common phenomenon that develops both from natural causes and during major operations. Many intracellular processes mediated by calcium ions are involved in the development of IRI. Currently, chemical calcium channel blockers are used but they have a number of limitations. In this article, we study the effect of the omega-hexatoxin-Hv1a peptide toxin, an alternative to chemical calcium channel blockers, on the mechanisms of IRI development in epithelial cell culture. The toxin was produced using solid phase peptide synthesis. IRI was caused by deprivation of glucose, serum and oxygen. The data obtained demonstrate that the omega-hexatoxin-Hv1a toxin in nanomolar concentrations is able to prevent the development of apoptosis and necrosis in epithelial cells by reducing the concentration of calcium, sodium and potassium ions, as well as by delaying rapid normalization of the pH level, affecting the mitochondrial potential and oxidative stress. This toxin can be used as an alternative to chemical calcium channel blockers for preventing tissue and organ IRI due to its low-dose requirement and high bioavailability.

show abstract

Section: Discussionmentioning

confidence: 99%